1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation

183490.KQ
Enzychem Lifesciences CorporationKR flagKOSDAQ
990.00
KRW
-27.00
- -
76.24BMarket Cap

Total Valuation

Enzychem Lifesciences Corporation carries a market capitalization of 76.24B, placing it among publicly traded companies globally. Its enterprise value stands at -20.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap76.24B
Enterprise Value-20.29B

Share Statistics

Enzychem Lifesciences Corporation currently has 77.01M shares outstanding.

Shares Outstanding77.01M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.24, and the price-to-book ratio stands at 1.83.

PE RatioN/A
PS Ratio1.24
PB Ratio1.83
P/TBV Ratio0.55
P/FCF Ratio-7.63
P/OCF Ratio-7.23

Enterprise Valuation

EV / Sales0.02
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Enzychem Lifesciences Corporation maintains a current ratio of 13.61, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.80, indicating elevated leverage, while an interest coverage ratio of -71.93 demonstrates limited ability to service its debt obligations.

Current Ratio13.61
Quick Ratio10.99
Debt / Equity3.80
Debt / EBITDA-0.42
Interest Coverage-71.93

Financial Efficiency

Return on Equity (ROE)-35.51
Return on Assets (ROA)-10.73
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.49

Taxes

Income Tax-130.53M
Effective Tax RateN/A

Stock Price Statistics

Enzychem Lifesciences Corporation's stock has declined approximately -17.5% over the past 52 weeks. The 50-day moving average sits at 1,204.26, while the 200-day moving average is 1,151.43.

Beta (5Y)N/A
52-Week Price Change-17.5%
50-Day Moving Average1,204.26
200-Day Moving Average1,151.43
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Enzychem Lifesciences Corporation generated 61.86B in revenue and converted that into -18.12B in net income, yielding earnings per share of -234.47. EBITDA reached -13.61B, while operating income came in at -13.61B.

Revenue61.86B
Gross Profit2.13B
Operating Income-13.61B
Pretax Income-18.29B
Net Income-18.12B
EBITDA-13.61B
EBIT-13.61B
Earnings Per Share (EPS)-234.47

Balance Sheet

Enzychem Lifesciences Corporation holds 104.01B in cash and equivalents against 5.70B in total debt, resulting in a net debt position of -9.23B. Total book value stands at 41.87B, with working capital of 119.39B providing operational flexibility.

Cash & Cash Equivalents104.01B
Total Debt5.70B
Net Debt-9.23B
Equity (Book Value)41.87B
Book Value Per Share540.47
Working Capital119.39B

Cash Flow

Enzychem Lifesciences Corporation produced -10.61B in operating cash flow over the past twelve months. After subtracting -560.49M in capital expenditures, free cash flow totaled -11.17B - equivalent to -144.20 per share.

Operating Cash Flow-10.61B
Capital Expenditures-560.49M
Free Cash Flow-11.17B
FCF Per Share-144.20

Margins

Enzychem Lifesciences Corporation operates with a gross margin of 3.45, reflecting its pricing power and cost economics. The operating margin of -22.00 and net profit margin of -29.29 provide insight into operational efficiency.

Gross Margin3.45
Operating Margin-22.00
Pretax Margin-29.57
Profit Margin-29.29
EBITDA Margin-22.00

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.11
FCF Yield-13.10

Stock Splits

Enzychem Lifesciences Corporation's most recent stock split took place on August 17, 2022 with a 1:6 split ratio.

Last Split Date8/17/2022
Split Ratio1:6

Scores

Enzychem Lifesciences Corporation posts an Altman Z-Score of 5.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.17